Bempedoic Acid

SAN DIEGO — In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse CV events by 30% compared with placebo, researchers reported.

The American College of Cardiology Scientific Session was held March 4 to 6 in New Orleans. Healio | Cardiology Today was on-site for the latest news in cardiology and experts’ reactions to it.

Healio and Cardiology Today have aggregated the top cardiology headlines of March 2023.

In the past decade, there have been major advances in lipid-lowering therapeutics, and another was made apparent in March at the American College of Cardiology Scientific Session.

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 4-6, 2023 in New Orleans and online.

LDL reduction is the major focus in the primary and secondary prevention of atherosclerotic CVD.

The American College of Cardiology issued an expert consensus decision pathway to address new lipid-lowering agents and other developments since the release of the ACC/American Heart Association cholesterol guidelines in 2018.

The cholesterol benefits of bempedoic acid plus background therapy were consistent across subgroups of patients with hypertension, metabolic syndrome and renal impairment, researchers reported.

High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.